Loading...
A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up
In phase II oncology trials, the use of new cytostatic drugs raises some questions regarding the endpoint. Time-to-event endpoints such as Progression-Free Survival have been recommended and led to new designs. In 2003, Case and Morgan proposed a design based on the comparison of the cumulative haza...
Na minha lista:
| Udgivet i: | Contemp Clin Trials Commun |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5898579/ https://ncbi.nlm.nih.gov/pubmed/29696201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2017.09.010 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|